When Nicole Stovall stepped into her new role as Chief Diversity Officer at Merck, it wasn’t just another career milestone—it was the manifestation of years of purpose, persistence, and faith […] ...
Findings from a phase 3 study provided additional evidence that the first pneumococcal vaccine made specifically for adults ...
Federal regulators have begun a safety review of 2 RSV medicines used to protect infants, even though no safety problems have been reported.
Private jets owned by six of the largest U.S. drugmakers have touched down in Washington-area airports 127 times this year, ...
Fintel reports that on December 12, 2025, Morgan Stanley maintained coverage of Merck (NYSE:MRK) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 7.23% Upside As of December 5, 2025 ...
BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...
The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
HealthDay News — Federal officials say the US Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and children following COVID-19 vaccination. Federal officials say ...
Get the latest Takeda (TAK) stock analysis. Read about risks, future prospects, and why peers may offer better value for ...
Preoperative radiation improved T-cell infiltration among patients with hormone receptor-positive, HER2-negative breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback